24.46
price down icon0.49%   -0.115
 
loading
Pfizer Inc stock is traded at $24.46, with a volume of 17.32M. It is down -0.49% in the last 24 hours and up +2.43% over the past month. Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$24.58
Open:
$24.71
24h Volume:
17.32M
Relative Volume:
0.41
Market Cap:
$139.09B
Revenue:
$62.46B
Net Income/Loss:
$7.88B
P/E Ratio:
17.73
EPS:
1.38
Net Cash Flow:
$11.22B
1W Performance:
-4.64%
1M Performance:
+2.43%
6M Performance:
-7.00%
1Y Performance:
-17.67%
1-Day Range:
Value
$24.42
$24.78
1-Week Range:
Value
$24.42
$25.63
52-Week Range:
Value
$20.91
$31.54

Pfizer Inc Stock (PFE) Company Profile

Name
Name
Pfizer Inc
Name
Phone
(212) 733-2323
Name
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Name
Employee
81,000
Name
Twitter
@Pfizer
Name
Next Earnings Date
2025-02-04
Name
Latest SEC Filings
Name
PFE's Discussions on Twitter

Compare PFE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
PFE
Pfizer Inc
24.46 146.57B 62.46B 7.88B 11.22B 1.38
Drug Manufacturers - General icon
LLY
Lilly Eli Co
770.49 709.79B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
164.16 379.41B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
188.92 344.45B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
114.67 244.38B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
64.30 315.52B 43.59B 15.04B 10.74B 3.3766

Pfizer Inc Stock (PFE) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-22-25 Initiated Cantor Fitzgerald Neutral
Dec-10-24 Resumed BofA Securities Neutral
Nov-15-24 Initiated Wolfe Research Underperform
Oct-25-24 Resumed Citigroup Neutral
Oct-17-24 Initiated Bernstein Mkt Perform
Aug-07-24 Upgrade Daiwa Securities Neutral → Outperform
Mar-22-24 Downgrade Argus Buy → Hold
Feb-23-24 Initiated Guggenheim Buy
Jan-04-24 Downgrade TD Cowen Outperform → Market Perform
Oct-20-23 Resumed UBS Neutral
Oct-16-23 Upgrade Jefferies Hold → Buy
Jul-17-23 Reiterated JP Morgan Neutral
Jul-14-23 Initiated HSBC Securities Buy
Jun-29-23 Downgrade Credit Suisse Outperform → Neutral
May-11-23 Downgrade Daiwa Securities Outperform → Neutral
Mar-06-23 Initiated Jefferies Hold
Feb-07-23 Upgrade Daiwa Securities Neutral → Outperform
Jan-26-23 Downgrade UBS Buy → Neutral
Jan-17-23 Downgrade Wells Fargo Overweight → Equal Weight
Jan-04-23 Downgrade BofA Securities Buy → Neutral
Dec-13-22 Upgrade Goldman Neutral → Buy
Nov-18-22 Initiated Credit Suisse Outperform
May-23-22 Initiated SVB Leerink Mkt Perform
Apr-06-22 Resumed Morgan Stanley Equal-Weight
Jan-05-22 Upgrade BofA Securities Neutral → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-20-21 Reiterated Cowen Outperform
Dec-17-21 Initiated Goldman Neutral
Dec-13-21 Upgrade UBS Neutral → Buy
Dec-09-21 Initiated Wells Fargo Overweight
Nov-19-21 Initiated BMO Capital Markets Outperform
Jul-27-21 Resumed Truist Buy
May-06-21 Downgrade Mizuho Buy → Neutral
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Feb-04-21 Upgrade DZ Bank Hold → Buy
Dec-16-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-20 Resumed Goldman Neutral
Nov-10-20 Resumed Bernstein Mkt Perform
Oct-12-20 Downgrade Atlantic Equities Overweight → Neutral
Sep-29-20 Initiated Berenberg Hold
Jun-16-20 Initiated SVB Leerink Mkt Perform
Feb-27-20 Initiated Barclays Equal Weight
Feb-27-20 Upgrade Standpoint Research Hold → Buy
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Outperform
Oct-17-19 Resumed BofA/Merrill Neutral
Jul-30-19 Downgrade BofA/Merrill Buy → Neutral
Jul-30-19 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-04-19 Resumed Morgan Stanley Overweight
Feb-20-19 Resumed Citigroup Neutral
Jan-31-19 Upgrade Argus Hold → Buy
Jan-31-19 Upgrade Credit Suisse Neutral → Outperform
Jan-23-19 Downgrade UBS Buy → Neutral
Dec-11-18 Downgrade JP Morgan Overweight → Neutral
Nov-01-18 Downgrade BMO Capital Markets Outperform → Market Perform
View All

Pfizer Inc Stock (PFE) Latest News

pulisher
07:02 AM

Rx Rundown: Sarep­ta Ther­a­peu­tics, Juul, Pfizer and more - Medical Marketing and Media

07:02 AM
pulisher
06:40 AM

BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum

06:40 AM
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters

Jul 17, 2025
pulisher
Jul 17, 2025

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit - insights.citeline.com

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off - Benzinga

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer (PFE) Expands Patient Access With Eliquis (Apixaban) Direct Purchase Program - simplywall.st

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer’s EPIC-Peds Study: A Potential Game-Changer for Pediatric COVID-19 Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer’s Phase 1 Study on PF-07941944: Key Insights for Investors - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer’s Pediatric Leukemia Study: Implications for BESPONSA’s Market Potential - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to offer Eliquis at a discount for some patients - BioPharma Dive

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer, Lilly spend big on telehealth contracts: Lawmaker report - Sherwood News

Jul 17, 2025
pulisher
Jul 17, 2025

Major drugmakers offer big discount on blood thinner Eliquis - Fox Business

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol-Myers Squibb (BMY) and Pfizer (PFE) Stocks Jump on Eliquis Drug Discount - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients - Reuters

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer Inc.'s (NYSE:PFE) recent 3.7% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance

Jul 17, 2025
pulisher
Jul 17, 2025

Lifestyle Drugs Market Future Business Opportunities - openPR.com

Jul 17, 2025
pulisher
Jul 17, 2025

How Bristol Myers Squibb and Pfizer's Direct-to-Patient Eliquis Initiative is Reshaping Anticoagulant Access and Profitability - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Drugmakers to Sell Popular Blood Thinner Eliquis at 40% Discount - Bloomberg.com

Jul 17, 2025
pulisher
Jul 17, 2025

BMS-Pfizer alliance to offer Eliquis at 40% discount to cash-paying patients - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer Slash Eliquis Price by 40% with New Direct-to-Patient Program for Top Blood Thinner - Stock Titan

Jul 17, 2025
pulisher
Jul 17, 2025

Exclusive | Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount - The Wall Street Journal

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer To Offer Blood Thinning Drug At Discount: Retail Chatter Around BMY Jump 60% In 24 Hours - Stocktwits

Jul 17, 2025
pulisher
Jul 16, 2025

4 High-Yield Large-Caps With Dividend Risk and Opportunity in Focus - Investing.com

Jul 16, 2025
pulisher
Jul 16, 2025

Pfizer’s Latest Clinical Study: A New Hope for Advanced Melanoma Treatment? - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

Pfizer’s INLYTA® Study Completion: Real-World Insights and Market Impact - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

Pfizer’s Hemophilia Study Completion: Market Implications and Insights - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

AbbVie and Pfizer’s Promising Study on Lung Cancer Treatment: A Market Game-Changer? - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

Pfizer’s BeneFIX Study Completion: Market Implications and Insights - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

Pfizer Subsidiary Recalls Bicillin L-A; South Dakota Department of Health Advises Caution - mykxlg.com

Jul 16, 2025
pulisher
Jul 16, 2025

Jim Cramer Says Pfizer Needs a Catalyst - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

NYC Mayor Race: Mamdani Talks 'Intifada', Taxes in Grilling by Business Leaders - Bloomberg

Jul 15, 2025
pulisher
Jul 15, 2025

Pfizer (PFE) Shares Cross 7% Yield Mark - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

Japan discards 2.5m doses of expired COVID drugs from Pfizer, Merck - Nikkei Asia

Jul 15, 2025
pulisher
Jul 15, 2025

How Will Pfizer's Oncology Drugs Perform in Q2 Earnings? - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

Pfizer Plummets 2.4%—Is Oncology's Growth Spree Over? - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Morningstar Reduces Moat Rating For Pfizer (PFE) To Narrow - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Ex-Pfizer Doctor Tells Congress He Didn’t Delay Covid Shot Data - Bloomberg.com

Jul 15, 2025
pulisher
Jul 15, 2025

Pfizer describes new STAT6 inhibitors - BioWorld MedTech

Jul 15, 2025
pulisher
Jul 15, 2025

She helped launch Pfizer's COVID-19 vaccine in the depths of the pandemic. Now, she's planning her next act. - Business Insider

Jul 15, 2025
pulisher
Jul 15, 2025

TD Cowen Adjusts Price Target on Pfizer to $30 From $28, Maintains Hold Rating - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Oxford BioDynamics shares jump 118% after Pfizer validates blood-based cancer biomarker technology - Proactive Investors

Jul 15, 2025
pulisher
Jul 14, 2025

Pfizer (PFE) Stock Sinks As Market Gains: Here's Why - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook - Benzinga

Jul 14, 2025
pulisher
Jul 14, 2025

Pfizer’s Phase 3 Study on PF-06821497: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

Pfizer’s New Phase 3 Study: A Potential Game-Changer in Prostate Cancer Treatment? - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know - Yahoo Finance

Jul 14, 2025
pulisher
Jul 13, 2025

Pfizer (PFE) Reports XTANDI Shows Life-Extending Benefits - Insider Monkey

Jul 13, 2025
pulisher
Jul 12, 2025

Pfizer Earnings Preview: What to Expect - MSN

Jul 12, 2025
pulisher
Jul 12, 2025

Pfizer's Legal Crossroads: Navigating Risks and Opportunities in Pharma Litigation - AInvest

Jul 12, 2025
pulisher
Jul 12, 2025

Pfizer Inc. - Britannica

Jul 12, 2025
pulisher
Jul 11, 2025

Pfizer’s Study on Rimegepant and Pregnancy: What Investors Need to Know - TipRanks

Jul 11, 2025

Pfizer Inc Stock (PFE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$110.21
price up icon 0.49%
drug_manufacturers_general SNY
$48.54
price down icon 0.23%
$298.28
price up icon 0.08%
drug_manufacturers_general MRK
$81.53
price up icon 0.01%
drug_manufacturers_general NVO
$65.18
price down icon 0.00%
Cap:     |  Volume (24h):